CN104159609A - 用于预防锦鲤疱疹病毒(khv)引起的疾病的重组khv和疫苗 - Google Patents
用于预防锦鲤疱疹病毒(khv)引起的疾病的重组khv和疫苗 Download PDFInfo
- Publication number
- CN104159609A CN104159609A CN201280065496.XA CN201280065496A CN104159609A CN 104159609 A CN104159609 A CN 104159609A CN 201280065496 A CN201280065496 A CN 201280065496A CN 104159609 A CN104159609 A CN 104159609A
- Authority
- CN
- China
- Prior art keywords
- restructuring
- khv
- koi herpesvirus
- gene
- bac
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001051708 Cyprinid herpesvirus 3 Species 0.000 title claims abstract description 176
- 229960005486 vaccine Drugs 0.000 title claims abstract description 49
- 201000010099 disease Diseases 0.000 title claims abstract description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 22
- 230000002265 prevention Effects 0.000 title abstract description 3
- 241000252233 Cyprinus carpio Species 0.000 claims abstract description 71
- 241000251468 Actinopterygii Species 0.000 claims abstract description 59
- 238000000034 method Methods 0.000 claims abstract description 23
- 210000004436 artificial bacterial chromosome Anatomy 0.000 claims description 120
- 108090000623 proteins and genes Proteins 0.000 claims description 72
- 210000004027 cell Anatomy 0.000 claims description 39
- 208000015181 infectious disease Diseases 0.000 claims description 33
- 108020004414 DNA Proteins 0.000 claims description 30
- 230000007547 defect Effects 0.000 claims description 24
- 108020004440 Thymidine kinase Proteins 0.000 claims description 17
- 241001529453 unidentified herpesvirus Species 0.000 claims description 17
- 230000002458 infectious effect Effects 0.000 claims description 14
- 230000001018 virulence Effects 0.000 claims description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
- 239000012634 fragment Substances 0.000 claims description 12
- 238000003780 insertion Methods 0.000 claims description 8
- 230000037431 insertion Effects 0.000 claims description 8
- 206010058874 Viraemia Diseases 0.000 claims description 7
- 230000010076 replication Effects 0.000 claims description 7
- 230000000735 allogeneic effect Effects 0.000 claims description 6
- 108010000742 dTMP kinase Proteins 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 5
- 101000818123 Acholeplasma phage L2 Uncharacterized 17.2 kDa protein Proteins 0.000 claims description 4
- 108090000288 Glycoproteins Proteins 0.000 claims description 4
- 102000003886 Glycoproteins Human genes 0.000 claims description 4
- 101000854890 Haemophilus phage HP1 (strain HP1c1) Probable terminase, ATPase subunit Proteins 0.000 claims description 4
- 101000818121 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 18.2 kDa protein in rep-hol intergenic region Proteins 0.000 claims description 4
- 101000768945 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 7.9 kDa protein in int-C1 intergenic region Proteins 0.000 claims description 4
- 101000578717 Klebsiella pneumoniae Mannose-1-phosphate guanylyltransferase Proteins 0.000 claims description 4
- 101000790842 Klebsiella pneumoniae Uncharacterized 65.4 kDa protein in cps region Proteins 0.000 claims description 4
- 101000781204 Orgyia pseudotsugata multicapsid polyhedrosis virus Uncharacterized 36.6 kDa protein Proteins 0.000 claims description 4
- 101000755099 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized protein Synpcc7942_2126 Proteins 0.000 claims description 4
- 101000768322 Synechococcus sp. (strain WH8020) Uncharacterized 16.1 kDa protein in cpeY 3'region Proteins 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 108700026244 Open Reading Frames Proteins 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 241001090021 Cyprinus carpio carpio Species 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 101000814063 Salmonella phage P22 Uncharacterized 6.6 kDa protein in eae-abc2 intergenic region Proteins 0.000 description 48
- 239000013612 plasmid Substances 0.000 description 46
- 241000700605 Viruses Species 0.000 description 45
- 101150045500 galK gene Proteins 0.000 description 38
- 239000002671 adjuvant Substances 0.000 description 21
- 230000008034 disappearance Effects 0.000 description 19
- 238000012360 testing method Methods 0.000 description 18
- 230000003612 virological effect Effects 0.000 description 18
- 230000006801 homologous recombination Effects 0.000 description 16
- 238000002744 homologous recombination Methods 0.000 description 16
- 101100170173 Caenorhabditis elegans del-1 gene Proteins 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 230000000844 anti-bacterial effect Effects 0.000 description 12
- 102000006601 Thymidine Kinase Human genes 0.000 description 11
- 238000011081 inoculation Methods 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 238000002255 vaccination Methods 0.000 description 11
- 238000000746 purification Methods 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 238000001890 transfection Methods 0.000 description 9
- 108700005077 Viral Genes Proteins 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 238000004520 electroporation Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 7
- 210000002845 virion Anatomy 0.000 description 7
- 108010051219 Cre recombinase Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 238000006062 fragmentation reaction Methods 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 230000009385 viral infection Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000013467 fragmentation Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 108091093088 Amplicon Proteins 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 101000827754 Rhodobacter capsulatus Uncharacterized 5.8 kDa protein in puhA 5'region Proteins 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000003308 immunostimulating effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 102000048120 Galactokinases Human genes 0.000 description 3
- 108700023157 Galactokinases Proteins 0.000 description 3
- 229920001503 Glucan Polymers 0.000 description 3
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 3
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 3
- 229940031567 attenuated vaccine Drugs 0.000 description 3
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 3
- 229940097572 chloromycetin Drugs 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 102000003390 tumor necrosis factor Human genes 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000011238 DNA vaccination Methods 0.000 description 2
- 206010012441 Dermatitis bullous Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241001068263 Replication competent viruses Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101000814062 Streptomyces lividans Uncharacterized 6.0 kDa protein Proteins 0.000 description 2
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000013326 plasmid cotransfection Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 229940125575 vaccine candidate Drugs 0.000 description 2
- 239000007762 w/o emulsion Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical class O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241001330002 Bambuseae Species 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101000748745 Chlamydomonas reinhardtii Uncharacterized 6.2 kDa protein in psaC-petL intergenic region Proteins 0.000 description 1
- 241001315730 Cyprinid herpesvirus 2 Species 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- 241000701372 Iridovirus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910000318 alkali metal phosphate Inorganic materials 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- -1 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000004495 emulsifiable concentrate Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 239000003752 hydrotrope Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- QUCDWLYKDRVKMI-UHFFFAOYSA-M sodium;3,4-dimethylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1C QUCDWLYKDRVKMI-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940124856 vaccine component Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16041—Use of virus, viral particle or viral elements as a vector
- C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16061—Methods of inactivation or attenuation
- C12N2710/16062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Farming Of Fish And Shellfish (AREA)
Abstract
Description
Claims (15)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11196171.0 | 2011-12-30 | ||
EP11196171 | 2011-12-30 | ||
PCT/EP2012/076496 WO2013098214A1 (en) | 2011-12-30 | 2012-12-20 | A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104159609A true CN104159609A (zh) | 2014-11-19 |
CN104159609B CN104159609B (zh) | 2018-05-22 |
Family
ID=47429841
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280065496.XA Active CN104159609B (zh) | 2011-12-30 | 2012-12-20 | 用于预防锦鲤疱疹病毒(khv)引起的疾病的重组khv和疫苗 |
Country Status (18)
Country | Link |
---|---|
US (2) | US20140348875A1 (zh) |
EP (1) | EP2797627B1 (zh) |
JP (3) | JP5982009B2 (zh) |
CN (1) | CN104159609B (zh) |
BR (1) | BR112014016117A2 (zh) |
HU (1) | HUE053075T2 (zh) |
IL (1) | IL232902A0 (zh) |
IN (1) | IN2014CN04655A (zh) |
MD (1) | MD4481C1 (zh) |
MX (1) | MX361408B (zh) |
PH (1) | PH12014501388A1 (zh) |
PL (1) | PL2797627T3 (zh) |
RS (1) | RS61261B1 (zh) |
RU (1) | RU2662768C2 (zh) |
SG (1) | SG11201403066TA (zh) |
TW (1) | TWI484034B (zh) |
UA (2) | UA114719C2 (zh) |
WO (1) | WO2013098214A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110101854A (zh) * | 2019-05-14 | 2019-08-09 | 四川农业大学 | 一种鲤疱疹病毒ⅲ型疫苗及其制备方法 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS61261B1 (sr) * | 2011-12-30 | 2021-01-29 | Gesval S A | Rekombinantni koi herpesvirus (khv) i vakcina za prevenciju bolesti prouzrokovane khv |
US11174468B2 (en) * | 2016-04-08 | 2021-11-16 | William Marsh Rice University | Galactose utilization |
RU2736472C2 (ru) * | 2016-11-18 | 2020-11-17 | Общество с ограниченной ответственностью "ЭКСИФАРМ" | Химерный белок, синтетическая днк, кодирующая указанный белок, экспрессионный вектор, штамм-продуцент синтетической днк и способ получения плазмидной днк |
CN112321685B (zh) * | 2018-11-05 | 2022-02-18 | 深圳技术大学 | 用于鱼类预防或治疗CyHV-2感染的试剂及其应用 |
EP3662929A1 (en) * | 2018-12-07 | 2020-06-10 | IDT Biologika GmbH | A recombinant koi herpesvirus (khv) and a diva vaccine for preventing and/or treating a disease caused by khv |
CN110468111B (zh) * | 2019-08-07 | 2022-06-17 | 西北农林科技大学 | 一种展示CyHV-2膜蛋白的重组杆状病毒及其制备方法和应用 |
CN110452926B (zh) * | 2019-08-07 | 2022-06-17 | 西北农林科技大学 | 一种展示CyHV-2膜蛋白的重组杆状病毒及其制备方法和应用 |
CN113679832A (zh) * | 2021-05-24 | 2021-11-23 | 苏州大学 | 一种利用冷冻干燥制备杆状病毒载鲤疱疹病毒ii型dna疫苗的方法 |
CN115960903B (zh) * | 2022-12-23 | 2023-09-08 | 中国水产科学研究院淡水渔业研究中心 | 一种抑制CyHV-2病毒增殖的反义RNA组、重组载体和纳米粒递送系统及应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1742083A (zh) * | 2003-01-01 | 2006-03-01 | 耶路撒冷希伯来大学伊萨姆研发公司 | 对鱼进行抗病毒感染的免疫 |
WO2009027412A1 (en) * | 2007-08-28 | 2009-03-05 | Universite De Liege | A recombinant koi herpesvirus (khv) or cyprinid herpesvirus 3 (cyhv-3) and a vaccine for the prevention of a disease caused by khv/cyhv-3 in cyprinus carpio carpio or cyprinus carpio koi |
CN101495636A (zh) * | 2006-04-13 | 2009-07-29 | 国立大学法人东京海洋大学 | 锦鲤疱疹病毒(khv)病用dna疫苗 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0382271B1 (en) | 1989-02-04 | 1994-12-21 | Akzo Nobel N.V. | Tocols as adjuvant in vaccine |
DE19733364A1 (de) | 1997-08-01 | 1999-02-04 | Koszinowski Ulrich H Prof | Verfahren zur Klonierung eines großen Virusgenoms |
JP2007223913A (ja) * | 2006-02-21 | 2007-09-06 | Kyoritsu Seiyaku Kk | コイヘルペスウイルス病ワクチン |
DE102007041332A1 (de) * | 2007-08-31 | 2009-03-05 | Siemens Ag | Transferchuck zur Übertragung, insbesondere von Wafern |
RS61261B1 (sr) * | 2011-12-30 | 2021-01-29 | Gesval S A | Rekombinantni koi herpesvirus (khv) i vakcina za prevenciju bolesti prouzrokovane khv |
-
2012
- 2012-12-20 RS RS20201561A patent/RS61261B1/sr unknown
- 2012-12-20 BR BR112014016117-8A patent/BR112014016117A2/pt not_active Application Discontinuation
- 2012-12-20 US US14/368,093 patent/US20140348875A1/en not_active Abandoned
- 2012-12-20 SG SG11201403066TA patent/SG11201403066TA/en unknown
- 2012-12-20 CN CN201280065496.XA patent/CN104159609B/zh active Active
- 2012-12-20 UA UAA201408626A patent/UA114719C2/uk unknown
- 2012-12-20 RU RU2014131474A patent/RU2662768C2/ru active
- 2012-12-20 WO PCT/EP2012/076496 patent/WO2013098214A1/en active Application Filing
- 2012-12-20 HU HUE12806062A patent/HUE053075T2/hu unknown
- 2012-12-20 UA UAA201702576A patent/UA119786C2/uk unknown
- 2012-12-20 JP JP2014549442A patent/JP5982009B2/ja active Active
- 2012-12-20 PL PL12806062T patent/PL2797627T3/pl unknown
- 2012-12-20 MX MX2014008045A patent/MX361408B/es active IP Right Grant
- 2012-12-20 EP EP12806062.1A patent/EP2797627B1/en active Active
- 2012-12-27 MD MDA20120127A patent/MD4481C1/ro not_active IP Right Cessation
- 2012-12-28 TW TW101150791A patent/TWI484034B/zh not_active IP Right Cessation
-
2014
- 2014-06-01 IL IL232902A patent/IL232902A0/en unknown
- 2014-06-18 PH PH12014501388A patent/PH12014501388A1/en unknown
- 2014-06-19 IN IN4655CHN2014 patent/IN2014CN04655A/en unknown
-
2016
- 2016-04-14 JP JP2016081363A patent/JP2016195593A/ja active Pending
- 2016-05-25 US US15/164,010 patent/US9931396B2/en active Active
-
2018
- 2018-01-11 JP JP2018002936A patent/JP2018078903A/ja not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1742083A (zh) * | 2003-01-01 | 2006-03-01 | 耶路撒冷希伯来大学伊萨姆研发公司 | 对鱼进行抗病毒感染的免疫 |
CN101495636A (zh) * | 2006-04-13 | 2009-07-29 | 国立大学法人东京海洋大学 | 锦鲤疱疹病毒(khv)病用dna疫苗 |
WO2009027412A1 (en) * | 2007-08-28 | 2009-03-05 | Universite De Liege | A recombinant koi herpesvirus (khv) or cyprinid herpesvirus 3 (cyhv-3) and a vaccine for the prevention of a disease caused by khv/cyhv-3 in cyprinus carpio carpio or cyprinus carpio koi |
Non-Patent Citations (1)
Title |
---|
B. COSTES等: "Cloning of the Koi Herpesvirus Genome as an Infectious Bacterial Artificial Chromosome Demonstrates That Disruption of the Thymidine Kinase Locus Induces Partial Attenuation in Cyprinus carpio koi", 《JOURNAL OF VIROLOGY》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110101854A (zh) * | 2019-05-14 | 2019-08-09 | 四川农业大学 | 一种鲤疱疹病毒ⅲ型疫苗及其制备方法 |
CN110101854B (zh) * | 2019-05-14 | 2022-08-02 | 四川农业大学 | 一种鲤疱疹病毒ⅲ型疫苗及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
TWI484034B (zh) | 2015-05-11 |
MD20120127A2 (en) | 2013-07-31 |
IN2014CN04655A (zh) | 2015-09-18 |
US20140348875A1 (en) | 2014-11-27 |
MX2014008045A (es) | 2014-10-24 |
PL2797627T3 (pl) | 2021-06-28 |
RS61261B1 (sr) | 2021-01-29 |
TW201333201A (zh) | 2013-08-16 |
WO2013098214A1 (en) | 2013-07-04 |
UA114719C2 (uk) | 2017-07-25 |
JP2015503914A (ja) | 2015-02-05 |
RU2662768C2 (ru) | 2018-07-31 |
RU2014131474A (ru) | 2016-02-20 |
JP2018078903A (ja) | 2018-05-24 |
US9931396B2 (en) | 2018-04-03 |
PH12014501388A1 (en) | 2014-09-22 |
JP2016195593A (ja) | 2016-11-24 |
EP2797627B1 (en) | 2020-10-07 |
MD4481B1 (ro) | 2017-05-31 |
MX361408B (es) | 2018-12-04 |
IL232902A0 (en) | 2014-07-31 |
MD4481C1 (ro) | 2017-12-31 |
HUE053075T2 (hu) | 2021-06-28 |
SG11201403066TA (en) | 2014-10-30 |
US20170028057A1 (en) | 2017-02-02 |
EP2797627A1 (en) | 2014-11-05 |
UA119786C2 (uk) | 2019-08-12 |
CN104159609B (zh) | 2018-05-22 |
JP5982009B2 (ja) | 2016-08-31 |
BR112014016117A2 (pt) | 2018-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2662768C2 (ru) | Рекомбинантный герпесвирус кои (khv) и вакцина для профилактики заболевания, вызываемого khv | |
US8728487B2 (en) | Attenuated live vaccine for prevention of porcine reproductive and respiratory syndrome | |
CN107805631B (zh) | 编码传染性喉气管炎病毒和新城疫病毒抗原的重组非致病性马立克氏病病毒构建体 | |
EP2195021B1 (en) | A recombinant koi herpesvirus (khv) or cyprinid herpesvirus 3 (cyhv-3) and a vaccine for the prevention of a disease caused by khv/cyhv-3 in cyprinus carpio carpio or cyprinus carpio koi | |
CN110628730B (zh) | 表达猪繁殖与呼吸综合征病毒gp蛋白的重组猪伪狂犬病病毒及应用 | |
CN113201507B (zh) | 一种重组的伪狂犬病病毒及其疫苗组合物 | |
JP7062760B2 (ja) | 昆虫細胞でのPCV2b ORF2タンパク質の組換え発現 | |
CN109310750B (zh) | 编码传染性喉气管炎病毒和传染性法氏囊病病毒抗原的重组非致病性马立克氏病病毒构建体 | |
JP2021500876A (ja) | 複数の異種抗原をコードする組換え非病原性マレック病ウイルス構築物 | |
CN104248757A (zh) | 猪伪狂犬病病毒疫苗组合物及其制备方法和应用 | |
JP2017526737A (ja) | 組み換え血清型9トリアデノウイルスベクター形式でのワクチン | |
Mebatsion | Introduction to Veterinary Vaccines | |
EP2031065A1 (en) | A recombinant koi herpesvirus (KHV) or Cyprinid herpesvirus 3 (CyHV-3) and a vaccine for the prevention of a disease caused by KHV/CyHV-3 in Cyprinus carpio carpio or Cyprinus carpio koi | |
WO2020115329A1 (en) | A recombinant koi herpesvirus (khv) and a diva vaccine for preventing and/or treating a disease caused by khv | |
CN113388641B (zh) | 一种禽4型腺病毒载体、构建方法及其减毒活疫苗和应用 | |
DE212022000331U1 (de) | Attenuiertes Lebendvirus von SARS-CoV-2 und ein daraus hergestellter Impfstoff | |
RU2507259C1 (ru) | РЕКОМБИНАНТНАЯ ПСЕВДОАДЕНОВИРУСНАЯ ЧАСТИЦА НА ОСНОВЕ ГЕНОМА АДЕНОВИРУСА ЧЕЛОВЕКА 5 СЕРОТИПА, ПРОДУЦИРУЮЩАЯ ГЕМАГГЛЮТИНИН ВИРУСА ГРИППА ШТАММА B/Brisbane/60/2008, СПОСОБ ЕЕ ИСПОЛЬЗОВАНИЯ ДЛЯ ИНДУКЦИИ СПЕЦИФИЧЕСКОГО ИММУНИТЕТА К ВИРУСУ ГРИППА В | |
CN117580588A (zh) | 对于鲤科鱼类疱疹病毒-2的疫苗 | |
CN116635069A (zh) | β冠状病毒低温驯化株和疫苗 | |
CN118813706A (zh) | 表达传染性法氏囊病病毒vp2基因的重组新城疫病毒疫苗株及其构建方法与应用 | |
Shchelkunov et al. | Vaccinia Virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160719 Address after: Belgium Aung San Applicant after: Gus Val AG Address before: Belgium Aung San Applicant before: University of Liege |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20141119 Assignee: NINGBO SANSHENG BIOLOGICAL TECHNOLOGY Co.,Ltd. Assignor: GESVAL S.A. Contract record no.: X2021990000218 Denomination of invention: Recombinant KHV and vaccine for prevention of diseases caused by Koi herpesvirus (KHV) Granted publication date: 20180522 License type: Exclusive License Record date: 20210413 |